October 26, 2016 6:13 AM ET


Company Overview of NeOnc Technologies, Inc.

Company Overview

NeOnc Technologies, Inc., a cancer biotechnology company, develops intranasal inhalation and other nontraditional delivery of a novel for the treatment of lung cancer, malignant brain cancer (gliomas), and other aggressive brain cancers. It offers NEO100, a purified form of the natural compound perillyl alcohol (POH); NEO102, an isoform of the natural compound POH; NEO106, a variant of the natural compound POH; NEO212, a chimeric molecule, where POH was permanently conjugated to temozolomides; and NEO214, a chimeric molecule, where POH was permanently conjugated to rolipram. The company was incorporated in 2008 and is based in Los Angeles, California.

8335 Sunset Boulevard

Suite 240

Los Angeles, CA 90069

United States

Founded in 2008





Key Executives for NeOnc Technologies, Inc.

Chairman, Chief Executive Officer, and Chief Scientific Officer
Chief Financial Officer and Director
Chief Operating Officer and Director
Age: 61
Senior Vice President of Corporate Affairs
Chief Regulatory Officer and Vice President
Age: 73
Compensation as of Fiscal Year 2016.

NeOnc Technologies, Inc. Key Developments

NeOnc Technologies, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-06-2016 11:30 AM

NeOnc Technologies, Inc. Presents at BioNetwork West Partnering Summit 2016, Oct-06-2016 11:30 AM. Venue: The Ritz-Carlton, Laguna Niguel, California, United States. Speakers: Thomas C. Chen, Chairman, Chief Executive Officer, and Chief Scientific Officer.

NeOnc Technologies Announces Initiation of Phase 1/2A Clinical Trial of NEO100™ in Recurrent Glioblastoma Multiforme

NeOnc Technologies, Inc. announced the initiation of its multi-center Phase 1/2a clinical trial of NEO100with the first patient being treated at the Cleveland Clinic. Additional clinical sites in Wisconsin, Washington, California, Utah, Florida, and Brazil are being qualified. NEO100 is the first GMP quality perillyl alcohol (POH) that is FDA approved for human clinical trials. An ongoing clinical trial [3] in Brazil using chemical grade POH has given encouraging results in patients with recurrent GBM, with a number of patients with recurrent GBM achieving extended survival (more than four years) using intranasal POH alone. It is anticipated that a total of approximately 40 patients will be enrolled in the trial over the next 18 months. NEO100 is a novel chemotherapeutic agent which was initially investigated by the National Cancer Institute. In those studies, the drug was given orally, and did not appear to be effective. In the NeOnc sponsored trial, like the study being conducted in Brazil, the drug is delivered intranasally. This is the first human clinical trial using this novel delivery method for brain tumors. Recurrent GBM is poorly treated by currently available therapies and thus is a serious unmet medical condition. Only 3-5% of patients with GBM survive for more than 5 years. The clinical study consists of two phases; first a dose escalation phase, followed by 25 patients being treated at the highest dose that is well tolerated. NEO100 is administered four times a day, with each treatment lasting about 15 minutes, and therapy is continued for up to 6 months. Minimal side-effects were experienced by the patients in Brazil.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NeOnc Technologies, Inc., please visit www.neonctech.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.